Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study by Augustin, M. et al.
ORIGINAL ARTICLE
Characteristics and outcomes of patients treated with
apremilast in the real world: results from the APPRECIATE
study
M. Augustin,1,* C.E. Kleyn,2 C. Conrad,3 P.G. Sator,4 M. Stahle,5 K. Eyerich,6 M.A. Radtke,7 C. Bundy,8
L. Mellars,9 C. Greggio,10 M. Cordey,11 V. Koscielny,10 C.E.M. Griffiths2
1Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg,
Germany
2The Dermatology Centre, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, UK
3Service of Dermatology and Venereology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
4Department of Dermatology, Hietzing Hospital, Vienna, Austria
5Unit of Dermatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
6Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany
7Dermatologikum Hamburg, Hamburg, Germany
8College of Biomedical and Health Sciences Cardiff University, Cardiff, UK
9Celgene Corporation, Summit, NJ, USA
10Celgene International, Boudry, Switzerland
11Amgen Europe GmbH, Rotkreuz, Switzerland
*Correspondence: M. Augustin. E-mail: m.augustin@uke.de
Abstract
Background APPRECIATE is a multinational, observational, retrospective, cross-sectional study in patients treated for
psoriasis with apremilast, an oral phosphodiesterase 4 inhibitor.
Objectives To describe the characteristics of patients with psoriasis treated with apremilast in the clinical setting, to
evaluate real-world outcomes of psoriasis treatment with apremilast and to better understand the perspectives of
patients and physicians on treatment outcomes.
Methods In six European countries, patients with chronic plaque psoriasis treated in clinical practice who could be
contacted 6 (1) months after apremilast initiation were enrolled. Patient characteristics, Dermatology Life Quality Index
(DLQI) and Psoriasis Area and Severity Index (PASI) were obtained from medical records when available. Outcomes were
evaluated using patient/physician questionnaires.
Results In 480 patients at treatment initiation, mean [median; 95% confidence interval (CI)] PASI and DLQI scores were
12.5 (10.7; 11.6–13.4) and 13.4 (13.0; 11.4–14.2), respectively. At 6 (1) months, 72.3% of patients (n = 347) continued
apremilast treatment [discontinuations: lack of efficacy (13.5%), safety (11.7%), other (2.5%)]. In patients continuing
treatment, 48.6% achieved a ≥75% reduction in PASI score; mean (95% CI) DLQI score was 5.7 (4.5–6.9), and mean
(SD) Patient Benefit Index score was 2.8 (1.2). Physicians perceived clinical improvement in 75.6% of patients. Physi-
cians’ perspective on overall success of apremilast in meeting expectations correlated with patients’ perception of treat-
ment benefit (r = 0.691). Most commonly reported adverse events (>5% of patients) were diarrhoea, nausea and
headache.
Conclusions Patients in APPRECIATE reported high disease burden despite more moderate skin involvement than
those who enrolled in clinical trials of apremilast. Findings from APPRECIATE demonstrate the real-world value of
apremilast for psoriasis treatment, as 7 of 10 patients continued therapy and showed notable improvement in disease
severity and quality of life 6 (1) months after apremilast initiation.
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Introduction
Psoriasis, a long-term immune-mediated inflammatory disease,1
is associated with several comorbidities, including psoriatic arthri-
tis (PsA) and cardiometabolic disorders.2–5 In addition to its clin-
ical burden, psoriasis has significant psychosocial impact.6 In
large surveys of patients with psoriasis, respondents have reported
that psoriasis can affect emotional state, interfere with daily life7
and have a negative impact on work, relationships and sleep.8
The impact of psoriasis on a patient’s daily life may not
always correlate directly with commonly used clinical measures
of disease severity.6,9,10 Current psoriasis treatment algorithms
and guidelines rely primarily on a clinician’s assessment of dis-
ease severity, such as body surface area (BSA) and Psoriasis Area
and Severity Index (PASI) and secondarily on patient-reported
quality of life (QOL) including the Dermatology Life Quality
Index (DLQI).11 Standard severity measures do not encompass
all factors that influence the disease burden.10,12 Additional fac-
tors, including involvement of highly visible or bothersome areas
(e.g. scalp, nails, genitals, palms and/or soles) or symptoms (e.g.
itching), significantly impair QOL and impact patient-perceived
severity.13–16 Failure to assess all factors of disease involvement
and associated symptoms may result in disparate physician and
patient treatment goals.17,18 Moderate-to-severe psoriasis has
been inadequately treated,19 and a European consensus state-
ment was developed to identify and provide treatment guidelines
for these patients.20
Apremilast is an oral phosphodiesterase 4 inhibitor first
approved in Europe for the treatment of adult patients with
moderate-to-severe chronic plaque psoriasis and PsA in
2015.21,22 In phase 3 and 4 placebo-controlled clinical studies,
apremilast demonstrated efficacy and safety in patients with
moderate-to-severe psoriasis previously treated with systemic
therapy (ESTEEM 1 and 2),21,23 in biologic-naive patients with
moderate-to-severe psoriasis (LIBERATE),24 and in systemic-
and biologic-naive patients with moderate psoriasis
(UNVEIL).25 There is a need to investigate the use and effective-
ness of apremilast in real-world settings.
The Apremilast Clinical Treatment Experience in Psoriasis
(APPRECIATE; NCT02740218) study, a multinational, observa-
tional, retrospective, cross-sectional study, was designed to
describe the characteristics of patients with psoriasis treated with
apremilast in the clinical setting, and to better understand treat-
ment needs and outcomes from the perspectives of both the
physician and the patient.26–28 To complement chart reviews
and validated patient-reported outcomes tools, questionnaires
were designed by expert consensus to capture perceived effec-
tiveness, convenience and global satisfaction beyond standard
disease assessment tools. This manuscript presents the results
from the six participating European countries.
Materials and methods
Setting
This study was designed to capture outcome data 6 months after
the initiation of apremilast treatment (Fig. 1). A 6-month time
point was chosen because the greatest improvement during piv-
otal clinical trials was observed within the first 24 weeks of treat-
ment.21,23–25 The analysis included patients and their physicians
from 87 sites in six European countries (Austria, Germany, Ire-
land, Sweden, Switzerland and the United Kingdom). Sites were
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selected based on their psoriasis management expertise, their
access to apremilast through local reimbursement or access
options and their research and governance capacity. Sites were
representative of urban and rural areas, and hospital, clinic and
private-practice settings. For sites that were considered for feasi-
bility but not included (N = 297), reasons for non-selection
(n = 165), non-participation (n = 14) and withdrawal (n = 11)
are described in the supplementary appendix (Figure S1, Sup-
porting Information). Patients were enrolled between May 2016
and July 2018 based on sequential opening of study sites in par-
ticipating countries.
Participants
Patients were aged 18 years or older with physician-diagnosed
chronic plaque psoriasis treated according to routine clinical
practice, who could be contacted 6 (1) months after apremilast
initiation. Patients were enrolled regardless of whether they were
continuing apremilast treatment. Per protocol, patients were
recruited consecutively at each site, and physicians were asked to
log non-enrolled patients to keep track of their apremilast treat-
ment status. All assessments were performed during routine clin-
ical visits. Patients who were participating in another clinical
trial were excluded from the study. The study was approved by
the relevant ethics committees (Table S1, Supporting Informa-
tion), and informed consent was obtained before any data col-
lection occurred. The research was conducted according to the
principles expressed in the Declaration of Helsinki.
Study medication
Apremilast treatment was initiated within the approved Euro-
pean Union (EU) label indication as per routine clinical practice;
study inclusion was not a factor in clinical decision-making.
Reimbursement criteria were largely similar across countries,
although in the United Kingdom and Ireland apremilast was
prescribed as part of an early patient access programme.
Data collection
Data were collected from three sources: medical records, physi-
cians and patients.
Medical records provided data on patient demographics, dis-
ease characteristics, apremilast status 6 (1) months after its ini-
tiation and adverse events (AEs). Disease characteristics
included disease severity (PASI and psoriasis-involved BSA),
presence of specific manifestations and symptoms of psoriasis
(scalp, nails, palmoplantar, genital, non-genital inverse, pruritus,
fatigue, palmoplantar pustulosis and PsA), a skin-related QOL
measure (DLQI) and prior phototherapy or systemic psoriasis
treatments. Disease severity scores were collected at follow-up
for patients remaining on apremilast therapy, and AEs were cap-
tured retrospectively. All data from medical records were entered
into a password-protected, web-based electronic data capture
(EDC) system by the physician.
Study-specific questionnaires were developed for both physi-
cians and patients based on expert consensus. These question-
naires assessed the needs and goals of patients in relation to their
Figure 1 Study design. DLQI, Dermatology Life Quality Index; TSQM-9, 9-item Treatment Satisfaction Questionnaire for Medication.
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psoriasis treatment, as well as the ability of apremilast to meet
patients’ expectations and physicians’ expectations on effective-
ness and overall treatment success.
For each enrolled patient, the treating physician completed
the study-specific physician questionnaire using the EDC sys-
tem. This questionnaire collected information on the reasons
for apremilast use, treatment effects on symptoms, treatment
tolerability, effectiveness of apremilast on individual psoriasis
symptoms (when data were available), fulfilment of expecta-
tions per symptom present at treatment initiation and over-
all success.
Patients were asked to complete three questionnaires 6 (1)
months after apremilast initiation: the study-specific question-
naire and two other validated questionnaires [the Patient Benefit
Index (PBI) for skin diseases and the 9-item Treatment Satisfac-
tion Questionnaire for Medication (TSQM-9), details of which
have been previously reported].29,30 The PBI consists of two
questionnaires: the Patient Needs Questionnaire (PNQ), typi-
cally administered before initiating a therapy to assess treatment
goals, and the Patient Benefit Questionnaire (PBQ), typically
administered at follow-up to assess the extent to which treat-
ment goals have been met.31 In APPRECIATE, owing to the ret-
rospective nature of data collection, both the PNQ and PBQ
were administered 6 (1) months after treatment initiation. The
questionnaires were completed by patients on paper and then
entered into the EDC system by the clinical research organiza-
tion (Kantar Health GmbH, Munich, Germany).
The study-specific patient questionnaire collected patient
demographics, socioeconomics, lifestyle factors, beliefs and
expectations plus experience of taking apremilast. Completed
patient questionnaires were reviewed for any AEs related to their
apremilast treatment.
Statistical analysis
This study is primarily descriptive; no a priori hypotheses were
identified. Patient demographics, disease characteristics, treat-
ment outcomes and AEs were summarized for all patients
enrolled using descriptive statistics; 95% confidence intervals
(CIs) were calculated. Missing values were not imputed. Results
were stratified by apremilast therapy status: ongoing versus dis-
continued. Correlations between outcome measures were calcu-
lated.
Results
Patient population characteristics
There were 605 patients contacted about participating in the
APPRECIATE study; 484/605 were enrolled. There were 4/484
patients who were excluded from the analysis because they were
later determined to be in violation of eligibility criteria. Reasons
for non-enrolment and violation are reported in Table S2, Sup-
porting Information.
The current analysis includes the 480 eligible patients (Ger-
many, n = 124; United Kingdom, n = 111; Switzerland, n = 83;
Sweden, n = 75; Austria, n = 72; and Ireland, n = 15) with a
diagnosis of chronic plaque psoriasis who had received apremilast
for the primary indication of plaque psoriasis. Of these patients,
462 (96.3%) completed questionnaires. Patient demographics and
psoriasis characteristics of enrolled patients at treatment initiation
are summarized in Table 1. Most patients (430; 89.6%) had
received at least one prior systemic psoriasis treatment, and 66
Table 1 Patient demographics and disease characteristics at
study initiation
Patient demographics Patients (N = 480)
Age, years
Median (range) 53.0 (18.0–89.0)
Mean (SD) 51.3 (15.2)
Gender, n (%)
Male 258 (53.8)
Female 222 (46.3)
Ethnicity and race, n (%)
White 371 (77.3)
South Asian 19 (4.0)
Asian (Chinese or other) 4 (0.8)
Black African 1 (0.2)
Other 22 (4.6)
BMI, kg/m2 (n = 196)
Median (range) 27.3 (17.0–53.0)
Mean (SD) 28.2 (6.3)
Disease characteristics
Time since diagnosis, years (n = 475)
Median (range) 15 (0–71)
Mean (SD) 18.6 (14.3)
PASI (n = 350)
Median (range) 10.7 (0.2–60.1)
Mean (SD) 12.5 (8.4)
PASI <10, n (%) 131 (37.4)
PASI ≥10, n (%) 219 (62.6)
BSA, % (n = 141)
Median (range) 16 (0–90)
Mean (SD) 25.4 (23.5)
DLQI (n = 205)
Median (range) 13 (0–30)
Mean (SD) 13.4 (7.5)
Comorbid conditions reported in >5% of patients, n (%)
PsA 124 (25.8)
Metabolic syndrome 70 (14.6)
Hypertension 57 (11.9)
Obesity 37 (7.7)
Depression 31 (6.5)
Specific manifestations of psoriasis
Pruritus, n (%) 325 (67.7)
Genital, n (%) 97 (20.2)
Non-genital, inverse, n (%) 73 (15.2)
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(13.8%) were receiving concomitant medication at treatment ini-
tiation (Table 1). The reasons cited for discontinuing previous
treatments were lack of efficacy (347; 72.3%), AEs (198; 41.3%),
too burdensome (42; 8.8%) and cost (4; 0.8%). The most com-
mon reasons for considering apremilast included ease of use (272;
56.7%), ineffective prior treatments (263; 54.8%), fewer side-ef-
fects compared with other treatments (254; 52.9%) and antici-
pated efficacy (241; 50.2%). Approximately half (237; 49.4%) of
all patients believed the decision to initiate apremilast was primar-
ily a joint decision with their healthcare provider, whereas 191
(39.8%) thought the physician was the primary decision-maker
and 23 (4.8%) that the decision had been primarily theirs.
At treatment initiation, mean (median; 95% CI) PASI and BSA
scores were 12.5 (10.7; 11.6–13.4; n = 350) and 25.4% (16.0%;
21.5–29.3%; n = 141), respectively. There was a small, positive
correlation between PASI and DLQI (r = 0.29; P < 0.0001;
n = 191; Figure S2, Supporting Information). Although 37.4% of
patients had a PASI score <10 at treatment initiation, the mean
(median; 95% CI) DLQI score was 13.4 (13.0; 12.4–14.4;
n = 205), indicating a very large impact of disease on QOL.
Apremilast treatment
After 6 (1) months, 72.3% of patients (n = 347) continued
apremilast treatment, with a mean duration of 6.0 months
(Table 2) at the time of the follow-up assessment. The propor-
tion of patients who continued apremilast treatment for 6 (1)
months was similar for those who were contacted but did not
enrol in the study (70.2%, 85/121). Enrolled patients who dis-
continued apremilast had a mean of 3.6 months (110.3 days) of
treatment.
Among patients continuing apremilast with disease scores
available at treatment initiation and at follow-up, an overall
55.5% improvement in PASI from treatment initiation was
reported. Mean (95% CI) PASI at follow-up was 4.6 (3.9–5.2;
Table 3). A ≥50% reduction in PASI (PASI-50 response) was
achieved by 68.9% (166/241) of patients, and a ≥75% reduction
in PASI (PASI-75 response) was achieved by 48.6% (117/241) of
patients. Mean (95% CI) DLQI score at follow-up was 5.7 (4.5–
6.9; n = 111) compared with 12.8 (11.4–14.2; n = 111) at treat-
ment initiation (Table 3; Figure S3, Supporting Information).
The extent of improvement in DLQI was largely comparable
across subgroups of patients with specific manifestations of pso-
riasis (Fig. 2). More than half (56.0%) of the patients with DLQI
score ≥5 at treatment initiation who were continuing treatment
achieved both PASI-50 response and a ≥5-point improvement in
DLQI. In patients with DLQI score ≥4 at treatment initiation,
66.0% (64/97) achieved an improvement at follow-up of ≥4
points (the recommended minimal clinically important differ-
ence for DLQI treatment response).
Physician satisfaction with apremilast treatment
Physicians reported clinical improvement in overall clearance of
plaque psoriasis in 75.6% (363/480) of patients. Specific mani-
festations including scalp, nail and palmoplantar involvement
were improved in 71.1% (231/325), 67.6% (123/182) and 75.4%
(86/114) of patients, respectively (Fig. 3a). Physicians also
reported clinical improvement of key clinical symptoms such as
pruritus (75.4%; 245/325) and fatigue (57.3%; 86/150) and
noted an improvement in overall well-being (69.0%; 331/480)
and ‘achieving a normal everyday life’ (64.6%; 310/480) for the
majority of enrolled patients. As expected, improvement ratings
were increased in patients who continued apremilast (Fig. 3b).
Table 1 Continued
Patient demographics Patients (N = 480)
Palmoplantar pustulosis 16 (3.3)
Highly visible locations, n (%) 388 (80.8)
Scalp 325 (67.7)
Nail 182 (37.9)
Palmoplantar 114 (23.8)
Prior systemic psoriasis treatment
Phototherapy,†n (%) 270 (56.3)
Conventional systemic therapy,‡n (%) 328 (68.3)
Biologic therapy,§n (%) 72 (15.0)
Concomitant medications for psoriasis reported for >2 patients
UVA/UVB 28 (5.8)
Glucocorticoids 10 (2.1)
NbUVB 8 (1.7)
Psoralen + UVA 7 (1.5)
Methotrexate 5 (1.0)
BMI, body mass index; BSA, body surface area; DLQI, Dermatology Life
Quality Index; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthri-
tis; SD, standard deviation.
†Phototherapy included UVA/UVB (114; 23.8%); nbUVB (99; 20.6%); and
psoralen + UVA (78; 16.3%).
‡Conventional systemic therapy included methotrexate (211; 44.0%); fuma-
ric acid esters (95; 19.8%); acitretin (59; 12.3%); ciclosporin (52; 10.8%); reti-
noids (31; 6.5%); glucocorticoids (20; 4.2%); leflunomide (7; 1.5%); and
sulfasalazine (3; 0.6%).
§Biologic therapy included adalimumab (42; 8.8%); etanercept (27; 5.6%);
ustekinumab (20; 4.2%); secukinumab (15; 3.1%); infliximab (9; 1.9%); efal-
izumab (3; 0.6%); and ixekizumab (2; 0.4%).
Table 2 Duration of treatment with apremilast
Group (N = 480) n (%) Duration of treatment (days)
Mean SD Median Range
Ongoing treatment 347 (72.3) 183.5 26.6 183.0 64–350
Discontinued treatment† 133 (27.7) 110.3 56.6 119.0 5–212
Lack of efficacy 65 (13.5) 137.4 40.9 138.0 49–212
Safety/tolerability 56 (11.7) 77.0 57.1 56.0 5–202
Other 9 (1.9) 110.6 41.3 114.5 58–161
Unknown 3 (0.6) 159.0 39.2 146.0 128–203
SD, standard deviation.
†Patients who discontinued treatment within 5–7 months after starting
apremilast. Duration of treatment data was missing for 5 patients who discon-
tinued treatment.
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Physicians believed that more than half (53.8%; 258/480) of
patients achieved or exceeded their treatment expectations with
apremilast (Fig. 3c).
Patient needs and satisfaction with apremilast treatment
Overall, the mean (SD) PBI score was 2.4 (1.4), and a PBI of ≥1,
which is considered to represent clinically meaningful benefit,29
was achieved by 78.7% of patients (Fig. 4a).
In patients who continued apremilast, mean (SD) PBI
score was 2.8 (1.2), and a PBI score ≥1 was achieved by
90.9% of patients (Fig. 4a). Based on the TSQM-9, patient
ratings of treatment effectiveness, convenience and global sat-
isfaction were >65 among patients who continued apremilast
(Fig. 4b).
Alignment of physicians’ expectations and patients’
expectations of treatment effects
Patients and physicians expressed similar levels of satisfaction
regarding onset and duration of treatment response to apremi-
last, the impact of treatment on specific manifestations of
Table 3 Clinical assessments at treatment initiation and follow-up†
Assessment at initiation and follow-
up
n Mean 95% CI SD Median Range (min–max)
PASI Treatment initiation 241 13.1 12.0–14.2 8.7 11.0 0.4–48.0
Follow-up 241 4.6 3.9–5.2 5.0 3.0 0–28.0
BSA (%) Treatment initiation 87 28.3 23.2–33.4 23.8 20.0 1.0–80.0
Follow-up 87 10.9 8.1–13.7 13.3 5.0 0–60.0
DLQI Treatment initiation 111 12.8 11.4–14.2 7.3 12.0 0–29.0
Follow-up 111 5.7 4.5–6.9 6.2 4.0 0–27.0
BSA, body surface area; CI, confidence index; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; SD, standard deviation.
†Patients with assessment at both treatment initiation and follow-up.
4.9
5.9
5.6
5.4
5.2
7.1
4.6
7.4
5.9
6.0
4.6
5.7
11.9
13.1
10.9
13.4
12.3
13.8
11.8
14.0
11.4
14.5
12.0
15.9
12.8
0 5 10 15 20
Treatment initiation
6 (±1) months treatment
Mean DLQI according to symptom manifestation
DLQI
Non-genital inverse (n = 20)
Genital involvement (n = 26)
Palmoplantar (n = 24)
Nail involvement (n = 46)
Scalp involvement (n = 78)
Pruritus (n = 70)
All patients (n = 111)
No non-genital inverse (n = 75)
No genital involvement (n = 63)
No palmoplantar (n = 74)
No nail involvement (n = 54)
No scalp involvement (n = 28)
No pruritus (n = 28)
7.2
Figure 2 Mean Dermatology Life Quality Index (DLQI) score at treatment initiation and follow-up by specific manifestations of psoriasis.
Data are for patients with assessments at treatment initiation and at 6 (1) months (follow-up) who were continuing apremilast treatment.
Error bars show 95% confidence intervals.
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psoriasis, reductions in itching and joint pain and improvement
in mood and overall well-being (Fig. 5). Physicians’ assessments
of the overall success of apremilast in meeting expectations
(Fig. 3c) and patients’ perception of benefit from therapy
(Fig. 4a) were positively correlated (Fig. 6). Strong agreement
was observed between physicians reporting that their
Judgement of Perceived Efficacy Outcome for Apremilast
(% of patients in category)b
Prevalence at 
Treatment Initiationa 
n (%)
(a)
Overall clearance of plaque psoriasis 480 (100.0)
Scalp psoriasis 325 (67.7)
Fatigue 150 (31.3)
Nail psoriasis 182 (37.9)
Pruritus 325 (67.7)
Palmoplantar psoriasis 114 (23.8)
Palmoplantar pustulosis 16 (3.3)
Non-genital inverse psoriasis 73 (15.2)
Genital psoriasis 97 (20.2)
Overall well-being 480 (100.0)
Achieving normal everyday life 480 (100.0)
0 25 50 75 100
27 23 14 25 10c
28 25 16 18 13c
36 15 19 26 4c 
44 19 19 13 6c
30 25 21 19 5c
37 22 16 21 4c 
27 23 17 32 1c 
27 13 17 33 10c
38 19 14 22 6c
36 23 16 16 8c
29 18 25 26 3c 
(b)
Judgement of perceived efficacy outcome for apremilast
(% of patients in category)d
Prevalence at 
treatment initiationa 
n (%)
Palmoplantar pustulosis
Overall clearance of plaque psoriasis
Palmoplantar psoriasis
Pruritus
Scalp psoriasis
Non-genital inverse psoriasis
Genital psoriasis
Overall well-being
Nail psoriasis
Achieving normal everyday life
Fatigue
347 (100.0)
235 (67.7)
103 (29.7)
143 (41.2)
226 (65.1)
83 (23.9)
13 (3.8)
51 (14.7)
72 (20.8)
347 (100.0)
347 (100.0)
0 25 50 75 100
34 27 16 22
41 28 21 10
54 23 15 8
35 24 29 12
44 18 19 18
47 27 15 8 2.6c
38 30 18 10 4.0c
37 16 19 25 2.9c
36 29 16 16 2.6c
48 22 14 14 1.3c
50 24 15 10 1.3c
No change
Moderately worse
Slightly worseMuch better
Moderately better
Much worseSlightly better
Figure 3 Physician judgement of perceived effectiveness outcomes for apremilast on psoriasis manifestations for all patients (a) and for
patients continuing apremilast treatment at 6 (1) months (b), and physician perceptions of overall success with apremilast treatment (c).
aIncludes patients with missing data (n = 2 for overall, n = 4 for scalp, n = 1 for palmoplantar). bChart data are for patients with clinical
signs and symptoms pre-apremilast initiation (patients with missing data are not shown). cSum of much, moderately and slightly worse
values. dIncludes patients with missing data (n = 1 for overall, n = 2 for scalp, n = 1 for palmoplantar).
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020
Real world use of apremilast: APPRECIATE study 7
expectations were achieved or exceeded and patients achieving
high benefit (PBI ≥3; Fig. 6).
Tolerability and safety
In total, 216 patients experienced at least one AE (Table 4); the
most commonly reported AEs [occurring in ≥5 (1%) patients]
were diarrhoea, nausea and headache. Likewise, the AEs most
frequently leading to treatment discontinuation were diarrhoea
(3.3%), nausea (3.3%) and headache (1.9%). Three patients
experienced serious AEs that were not suspected to be related to
apremilast (colon cancer, pancreatic carcinoma and myocardial
infarction; n = 1 for each). Four patients had serious AEs that
were suspected by the treating physician to be related to treat-
ment (gastritis, Guillain–Barre syndrome and dyspnoea, n = 1
for each; events of migraine, nightmare and night sweats were all
reported in one patient). The relationship of the case of Guil-
lain–Barre syndrome to apremilast treatment was based on the
timing of apremilast initiation and onset of symptoms; however,
prior respiratory infection may have been a confounding factor.
A total of 23.3% (112/480) of patients reported weight loss.
Mean (SD) weight loss was 6.2 (9.5) kg in patients who
reported weight loss and 1.0 (3.4) kg in all patients with weight
data (n = 195).
Discussion
Randomized clinical trials provide standardized and well-de-
fined measures of treatment efficacy in a specific patient popu-
lation; however, their outcomes may lack generalizability to
the diversity and complexity of real-world clinical practice.
Both the physician’s and the patient’s judgements of an indi-
vidual patient’s needs and clinical outcomes influence everyday
treatment decisions. The APPRECIATE study provided insight
into the treatment decisions that physicians and patients face
in daily life. A PASI score was recorded in 73% of patients at
treatment initiation, with scores <10 in approximately a third
of these patients. Importantly, the median DLQI score of >10
(mean, 13.4) indicates a very large impact of disease on QOL
at treatment initiation for most patients. This is in keeping
with previous findings that many patients treated with apremi-
last in clinical practice have more moderate skin involvement
than those participating in clinical trials, yet still perceive a
high burden of psoriasis on their QOL.21,23,25,32–37 Of note,
several European registries reported a greater mean PASI score
in patients initiated on biologic therapy, suggesting that in
clinical practice, where permissible geographically according to
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guidelines, apremilast is used in patients with more moderate
skin involvement and may therefore fill a key treatment need
for this patient population.32,38–43 Importantly, at treatment
initiation in APPRECIATE, PASI had a low correlation with
DLQI, indicating that the level of skin involvement is not the
only factor that patients take into account when assessing the
severity and impact of their disease. Recent studies have high-
lighted the difficulty of defining psoriasis severity44 and the
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Figure 5 Physician and patient questionnaire responses regarding the effect of treatment on symptoms for the full analysis set (a) and
for patients with ongoing treatment at 6 (1) months (b). Physicians completed a separate questionnaire for each patient. Question to
physician: ‘In what way do you think apremilast has helped this patient’s psoriasis specifically?’ Question to patient: ‘In what way do you
think apremilast has helped your psoriasis specifically?’ aData only for patients with the presence of psoriatic arthritis at treatment initia-
tion (full analysis set, n = 124; ongoing treatment set, n = 86).
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underestimation bias of the DLQI for patients with a high dis-
ease burden.45 For most enrolled patients, factors contributing
to the reported high burden of disease may include long-s-
tanding disease duration, prior systemic therapy failure,
comorbidities, pruritus and involvement of visible or high-
impact, bothersome locations such as the scalp, nails, genitals
and/or palmoplantar regions.
Although clinical assessment tools including the PASI are
commonly used to evaluate and study disease severity and treat-
ment efficacy, it is notable that only 107 of the 480 enrolled
patients (22.3%) in our study had documented PASI and DLQI
scores at treatment initiation and follow-up, indicating that
these tools are not used consistently in everyday practice to make
treatment decisions. This emphasizes the need to improve the
assessment of patients’ needs and treatment effectiveness beyond
traditional measures and to use patient-reported outcomes that
consider the impact on all aspects of patients’ daily lives. The
PBI for skin diseases captures patients’ treatment needs as well
as their perception of how well those needs are met by a given
therapy.29 In the current analysis, patients who remained on
apremilast therapy had improvements in PASI, BSA and DLQI,
and also self-reported benefits via the PBI and TSQM-9. Fur-
thermore, when comparing with patients who discontinued,
those who remained on therapy had higher scores on the
TSQM-9 subscales of effectiveness and satisfaction, but not con-
venience, suggesting that convenience was not the main driver
for persistence in this study. Overall, physicians and patients
reported similar satisfaction with apremilast treatment, includ-
ing quick onset of action, duration of treatment response, the
impact of treatment on specific manifestations and symptoms of
psoriasis (e.g. pruritus), and improvement in mood and overall
well-being. Treatment satisfaction with apremilast in APPRECI-
ATE was consistent with the results of the UNVEIL study, in
which patients reported satisfaction with the effectiveness, safety
and convenience of apremilast.25
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0 1 2 3 4
(no benefit) (maximum benefit)
Pearson correlation coefficient: 
Number of observations:
Exceeded
Achieved
Partially achieved
Did not meet
Ph
ys
ici
an
 a
ss
es
sm
en
t o
f o
ve
ra
ll s
uc
ce
ss
 
(ac
hie
ve
me
nt 
of 
ex
pe
cta
tio
ns
)
0.691369
451
Figure 6 Scatter plot of physician assessment of overall treatment success to global Patient Benefit Index (PBI). n = 451. Missing data
excluded.
Table 4 Overview of apremilast safety
Adverse events (AE), n (%) All patients (N = 480)
Patients with any AE 216 (45.0)
Patients with serious AE 7 (1.5)
Patients with AE leading to drug withdrawal 51 (10.6)
AE occurring in ≥1% of patients
Diarrhoea 90 (18.8)
Nausea 69 (14.4)
Headache 42 (8.8)
Fatigue 13 (2.7)
Weight decrease† 13 (2.7)
Arthralgia 7 (1.5)
Upper abdominal pain 7 (1.5)
Vomiting 7 (1.5)
Abdominal discomfort 6 (1.3)
Flatulence 6 (1.3)
Insomnia 6 (1.3)
Migraine 6 (1.3)
Dizziness 5 (1.0)
Dyspepsia 5 (1.0)
Depression 5 (1.0)
AE, adverse event.
†Medical records show mean weight loss: 1.5 kg (females, n = 94) and
0.6 kg (males, n = 101).
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Real-world studies allow for the assessment of treatments in
broad, diverse patient samples more representative of patients
seen in clinical practice. In addition, they allow observation of the
impact of disease and its treatment beyond standard clinical out-
comes and within the context of true treatment patterns. How-
ever, real-world clinical practice studies are limited by their lack
of a control group and reliance on the availability of assessments.
The effectiveness, tolerability and safety observed in our study
were consistent with findings in clinical trials of apremilast21,23,24;
however, our analyses were limited by the inconsistent use of
assessment tools at follow-up visits. The study also has the limita-
tions inherent to retrospective analyses. Recall bias cannot be
ruled out, although the 6-month follow-up period was chosen to
minimize the recall bias of retrospectively administered question-
naires while allowing sufficient time for treatment effects to
emerge. There was also a potential for patient selection bias
because patients with positive treatment experience may have
been more inclined to be contacted and available for enrolment.
Conclusions
Real-world studies can extend the existing knowledge of the
utility of new treatments by focusing on the acceptability and
everyday use of these treatments. The APPRECIATE study
importantly identified that, in clinical practice, patients who
initiated apremilast had more moderate skin involvement than
those who were enrolled in clinical trials of apremilast. Despite
more moderate psoriasis severity, most patients reported an
impact of psoriasis on their QOL at apremilast initiation that
was reflective of high disease burden. Taken together, findings
suggest that patients consider factors other than extent of skin
involvement when assessing the impact of psoriasis on QOL.
The results of this study highlight the need for a more com-
prehensive definition of psoriasis severity, which looks beyond
traditional skin-centric measures of PASI and DLQI to more
patient-centric measures, allowing for a more personalized
approach to evaluating the burden of psoriasis on patients’ lives
and impact of treatment. Efforts are underway to study the
impact of apremilast on QOL, efficacy and safety in people with
specific manifestations of plaque psoriasis and impaired QOL.
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